Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • 2020 Webinar: Current and Future Disease Burden of HBV: Global and Regional Perspectives

    Contains 2 Component(s) Recorded On: 09/18/2020

    Webinar hosted by the Hepatitis B Special Interest Group on September 18, 2020.

    In this on-demand webinar, representative speakers from Africa including North and Sub-Saharan Africa (Mark W. Sonderup, South Africa), East Asia (Jidong Jia, China), West and South Asia (Shiv K. Sarin, India), Europe including Western and Eastern Europe (George V. Papatheodoridis, Greece), North America (Carla Coffin, Canada) and South/Central America (Adrian Gadano) will each talk on HBV disease burden and primary challenges in their respective regions. They will present the current status and predictions for the next decade. The live question and answer session, the discussion will focus on the challenges and opportunities in each region.

    Participants will be able to:

    Have a global view from regional perspectives on the current situation and future prediction of HBV disease burden and to discuss the actions (most critical/effective/cost-effective) required to improve the predictions toward a more desirable goal in the region.

    Promote the global outreach of AASLD by addressing issues that interest local audience.

    Mark W. Sonderup

    Mark Sonderup, MBChB is an associate professor in the Department of Medicine and Division of Hepatology. In 1995, he graduated from the University of Cape Town. Following his internship training, his postgraduate training was at the University of Cape Town and Groote Schuur Hospital. He obtained a Fellowship of the College of Physicians in 2002. Between 2002 and 2004, he completed a 2-year fellowship in Hepatology at the UCT/Medical Research Council Liver Research Centre and Liver Clinic at Groote Schuur Hospital, Cape Town. He briefly worked in the UK before being appointed as a Senior Specialist in the Department of Medicine and Division of Hepatology at UCT and Groote Schuur Hospital in 2007. He was granted a FRCP (London) in 2018.

    Sonderup research interests include viral hepatitis and drug induced liver injuries. He assisted in co-authoring the national viral hepatitis guidelines and elimination strategy for South Africa. Currently he serves on the WHO Strategic Advisory Committee on Viral Hepatitis.

    Shiv K. Sarin

    Shiv K. Sarin, MD, FAASLD is the senior professor of hepatology and director of Institute of Liver and Biliary Sciences (ILBS), New Delhi. He was instrumental in setting up the Institute of Liver and Biliary Sciences, under the auspices of the Govt of Delhi. He is also the director, WHO Collaborative Centre on Chronic Liver diseases and Viral Hepatitis at ILBS. He serves as adjunct faculty, Molecular Medicine at JNU due to his deep interest and contributions to translational science. He was credited with several new treatment protocols for liver diseases, specifically variceal bleeding, liver regeneration, hepatitis B and acute-on-chronic liver failure. He has more than 620 publications to his credit, edited 13 books on liver diseases and contributed 87 chapters in various medical textbooks. He has helped develop 19 major guidelines: including six major Asian Pacific Treatment Guidelines in Liver diseases.

    Sarin’s leadership roles include serving as president of the Indian Society of Gastroenterology, Indian Association for the Study of the Liver, Asian Pacific Association of Liver (APASL) and chairman steering committee of the APASL. He was awarded the prestigious 2017 Henry L. Bockus Medal by World Gastroenterology Organization. He was bestowed with Padma Bhushan by the government of India. He was a recipient of Shanti Swarup Bhatnagar Award, The World Academy of Medical Sciences (TWAS) International Prize, EASL International Recognition Award, Om Prakash Bhasin Award, Dhanvantri Medical Award, Ranbaxy Medical Sciences Award and the ‘Best Teacher’ Award. He, along with other Board of Governors, developed the ‘Vision 2015’ document for Medical Education in India during his tenure as chairman of Medical Council of India.

    George V. Papatheodoridis

    George Papatheodoridis, MD, PhD, FAASLD is a professor in medicine and gastroenterology at Medical School of National and Kapodistrian University of Athens and Director of the Academic Gastroenterology Department and the Liver Transplantation Unit of “Laiko” General Hospital of Athens, Greece. He is also the president of the Hellenic Transplant Organization. In October 1986, he was trained in Medicine at the Medical School of Athens University and graduated with excellence (9.2/10). In February 1996, he completed his PhD thesis at the Medical School of Athens University. He was trained in Gastroenterology at Tzaneion Hospital of Piraeus, Greece and had a two-year research fellowship in Hepatology at the Royal Free Hospital of London, UK (01/1997-01/1999).

    Papatheodoridis has served in many international and national associations. He is a member of EASL and American Association for Study of Liver Diseases (AASLD fellow) and founding member and treasurer of Hepatitis B and C Public Policy Association. He is president of Hellenic Foundation of Gastroenterology and Nutrition. His main research interest has been focused on viral hepatitis. He has co-authored more than 315 papers published in PubMed journals having total IF>2000 and >1600/25000 citations (h-index 62/74) in Scopus/Google Scholar. He was an associate editor of Liver International and served as an editorial board member and reviewer of several international journals. He has given more than 160 lectures, chaired over 50 lectures/round tables and presented over 300 abstracts in international meetings.

    Carla S. Coffin

    Carla Coffin, MD is an associate professor of medicine (2016), Cumming School of Medicine, University of Calgary and Medical Director of the Calgary Liver Unit, Calgary Division of Gastroenterology and Hepatology, Alberta Health Services, Alberta, Canada. She received MSc degree using the woodchuck HBV model with Professor TI Michalak and MD from Memorial University of Newfoundland, NL. She completed Internal Medicine and Gastroenterology fellowship at the University of Calgary, AB followed by an American Association for the Study of Liver Disease (AASLD) Advanced Hepatology Fellowship with Professor NA Terrault at the University of California, San Francisco.

    Coffin was a recipient of a Canadian Institutes of Health Research (CIHR) New Investigator Award (2012-2017). Her research has been supported by CIHR, AASLD, the American Gastroenterology Association, Canadian Foundation for Innovation / Alberta Advanced Education Technology, Alberta Innovates and Industry partners. She was first author on the 2012 and 2018 Canadian Association for the Study of the Liver (CASL) Hepatitis B guidelines and is Chair of the CASL Education Committee (2019-2021). She served on the World Health Organization (WHO) Expert Advisory Panel on Drug Evaluation (2015) and extended as on call WHO advisor until 2021. She has an active translational research program in hepatitis B with 90 peer-reviewed publications, has participated in more than 20 hepatitis B clinical trials and was integral to establishing the Canadian Hepatitis B Research Network.

    Adrián C. Gadano

    Adrián Gadano, MD is an associate professor in Physiology, Gastroenterology and Hepatology at the Italian Hospital School of Medicine, Argentina. He oversees the Liver Unit and Medical Director of the Transplant Unit at the Italian Hospital in Buenos Aires. He is a consultant in Gastroenterology and Hepatology and has over 25 years in the management of patients affected with hepato-biliary diseases and liver transplantation. Gadano is chief of the Research Department at the same Institution. Since the early 1990’s, he conducted, coordinated and participated in several international and national clinical trials in the fields of viral hepatitis, complications of cirrhosis, hepatocellular carcinoma and liver transplantation.

    Gadano is a member of several intra-hospital and national committees, including the Argentinian Association for the Study of Liver Diseases (AAEEH), Argentinian Society of Gastroenterology (SAGE), the Argentinian Society of Transplantation (SAT). He is also a member of the Latin American Society of Liver Diseases (ALEH), the European Association of the Study of Liver Disease (EASL) and member of the board of Journal of Hepatology. He is part of the Board of the International Club of Ascitis (ICA). He was the president of the Argentinian Society of Transplantation (SAT), Argentinian Association for the Study of Liver Diseases (AAEEH) and the ICALMA Foundation. He has published over 150 original papers in official and peer-reviewed journals, and many other journal articles, book chapters and textbooks. He presented, during the last twenty years, hundreds of original papers at conferences and has chaired numerous sessions and symposia at national and international congresses.

    Jidong Jia

    Jidong Jia, MD, PhD, is a Hepatologist and Director of the Liver Research Centre at the Beijing Friendship Hospital, Capital University in Beijing, China. He is also immediate past President of the Chinese Society of Hepatology, Past President of APASL (2009-2010), Vice President of IASL. Dr. Jia also serves as associate editor for Journal of Gastroenterology & Hepatology, Hepatology International and Liver International. His clinical interests include the chronic viral hepatitis and autoimmune liver diseases. His research work mainly on cellular and molecular biology of the extracellular matrix of the liver and the pathogenesis and therapeutic study of experimental liver fibrosis.

    Mindie H. Nguyen (Moderator)

    Mindie Nguyen, MD is a professor of medicine and director for the Hepatology Fellowship and Clerkship in the Division of Gastroenterology and Hepatology and Liver Transplant at Stanford University Medical Center. She is an active clinician with a large general and transplant liver practice, and an active researcher in viral hepatitis, non-alcoholic fatty liver disease and liver cancer with over 250 publications including first or senior authorship in leading journals such as The New England Journal of Medicine, Lancet Gastroenterology and Hepatology, Gastroenterology, Journal of Hepatology and HEPATOLOGY.

    Nguyen has served as editorial/advisory board member for major journals such as Lancet Gastroenterology and Hepatology, Gastroenterology and HEPATOLOGY. She is currently Chair of the Hepatitis B Special Interest Group for the American Association for the Study of Liver Diseases (AASLD) and an Officer/Treasurer and Executive Governing Council for the International Association for the Study of Liver Diseases (IASL). She is the lead Principal Investigator for several multinational studies involving over 40 centers in the U.S. and Asia Pacific. She serves as Board of Directors or Advisors for non-profit organizations locally and nationally in the U.S; and in collaboration with the local country Ministries of Health and Sports, she has directed scientific programs of continuing medical conferences for physicians in Mongolia and Myanmar. As an active teacher and educator, she has mentored over 130 trainees from high school students to undergraduate, medical, Masters’ and PhD students in Public Health/Epidemiology, clinical residents/fellows, postdoctoral research fellows, and faculty at Assistant/Associate Professor rank from Stanford University as well as other institutions in the U.S. and overseas.

    Harry Janssen (Moderator)

    Harry Janssen, MD, PhD, FAASLD is a professor of medicine at the University of Toronto, Ontario, Canada, where he holds the Francis Family Chair in hepatology. He currently works at Toronto General Hospital as chief of hepatology and director of the Toronto Centre for Liver Disease.

    Dr. Janssen graduated from medical school in the Netherlands. During his study he spent one year as research student in Hepatology at the Mayo Clinic. He obtained his PhD in Rotterdam on the role of immune modulating therapy in hepatitis B. Following his training in Internal Medicine and Gastroenterology in the Netherlands, he returned to the Mayo Clinic for a Research Fellowship in Hepatology. In 2001, he became a faculty member and in 2006 he was appointed as full professor of medicine and chief of the Section Liver Diseases and Transplantation in Rotterdam. In 2013, he came to Canada where he merged three liver programs into the Toronto Centre for Liver Disease, based at the Toronto General Hospital, University Health Network.

    Dr. Janssen has coordinated numerous clinical and translational studies on treatment for chronic viral hepatitis and other liver diseases. His main research interest is cure of chronic hepatitis B. He has published more than 500 original peer-reviewed papers and many book chapters. His H-index is over 100 and he has been cited 45,000 times (Google Scholar). He has received several prestigious international awards and has mentored over 50 PhD students, of whom many have taken leadership positions in the field of hepatology or virology.

  • 2020 Webinar: Global Public Health Strategies for the Prevention of ALD in 2020

    Contains 2 Component(s) Recorded On: 09/01/2020

    Webinar hosted by the Alcohol-associated Liver Disease Special Interest Group on September 1, 2020.

    Alcohol-associated liver disease (ALD) is the leading cause of cirrhosis worldwide. Harmful drinking, especially among youth and women, is increasing.  A global alliance and discussion about effective public health strategies is needed. This webinar with a global outreach focus on ALD will involve the participation of the four major liver societies worldwide. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Alexandre Louvet

    Alexandre Louvet, MD is professor of hepatology in the gastroenterology department of the University Hospital of Lille, France, headed by Prof. Philippe Mathurin. He earned his medical degree from the University of Lille. He received his PhD degree after a fellowship in the Institut Mondor de Recherche Biomédicale in Créteil, France, where he worked on the role of the endocannabinoid system in alcoholic liver disease in mice. His clinical interests include alcoholic liver disease, non-alcoholic fatty liver disease, hepatocellular carcinoma and viral hepatitis.

    He is involved in both clinical and basic research. His main topic in research is alcoholic hepatitis (natural history, treatment, disease modeling, transplantation, and pathophysiology). He has published several papers on the management of patients with severe alcoholic hepatitis. He is a member of the governing board of the French Association for the Study of the Liver (AFEF), of the editorial board of the Journal of Hepatology and a reviewer for several journals specialized in hepatology.

    Cyriac Philips

    Cyriac Philips, MD, MBBS, DM is the Clinical Lead, The Liver Unit, Cochin Gastroenterology Group, based in Kochi, and Director of Monarch Liver Lab, Department of Clinical and Experimental Gastroenterology and Hepatology at the Ernakulam Medical Center Hospital, Kochi, Kerala, India. He is a two-time Clinical Hepatology plenary awardee (2015, 2017) of the American Association for Study of Liver Diseases (AASLD) and four-time AASLD and European Association for Study of Liver (EASL) Young Investigator Award winner (2015, 2016, 2017, 2017) and recipient of the prestigious President of India Excellence in Hepatology from Institute of Liver and Biliary Sciences, New Delhi in 2016. He has published over 140 peer-reviewed studies in high impact journals including Gastroenterology; HEPATOLOGY; Journal of Hepatology; Clinical Gastroenterology and Hepatology and the American Journal of Gastroenterology. His interests and expertise include study of the gut microbiome and its modulation in severe alcoholic hepatitis and sepsis, portosystemic shunt syndrome, drug induced liver injury especially Ayurvedic herbals and infections in cirrhosis. His pioneering work in the field of liver diseases has been the introduction of healthy donor fecal transplant for severe alcoholic hepatitis and novel data on clinical outcomes, toxicology and chemical analysis of Ayurvedic herbal induced liver injury for which he received the Indian National Award for Best Paper in 2019 from The Indian Society of Gastroenterology and SpringerNature.

    Juan Pablo Arab (Moderator)

    Juan Pablo Arab, MD is Assistant Professor of Medicine at the Pontificia Universidad Catolica de Chile School of Medicine. Trained at the P. Univ Catolica, Chile and Mayo Clinic, Rochester, MN, Dr. Arab is a Gastroenterology and Hepatology specialist, Transplant Hepatologist and Physician Scientist with interest in translational and clinical research in alcohol-associated liver disease and non-alcoholic fatty liver disease. He has published more than 90 peer-reviewed papers on gastrointestinal and liver diseases in high-impact factor journals, co-authored several book chapters and delivered lectures on liver-related topics at national and international meetings. He has also participated in the generation of clinical practice guidelines for alcohol-related liver disease, nonalcoholic fatty liver disease, and hepatorenal syndrome in Latin America and regularly serves as expert reviewer of research grants and scientific research abstracts for multiple societies, funding agencies and international peer reviewed journals. Additionally, he is spearheading an international collaboration group that aims to study alcohol-related liver disease and non-alcoholic fatty liver disease. Dr. Arab is a member of the American Association for the study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), and Latin-American Association for the Study of the Liver (ALEH). He is currently the Secretary of the Special Interest Group on alcohol-related liver disease of the AASLD and Vice-Chairs its global outreach subcommittee. Additionally, he is the Vice-President of the Chilean Hepatology Association.

    John P. Rice (Moderator)

    John P. Rice, MD is an Assistant Professor of Medicine and the Section Chief of Hepatology in the Division of Gastroenterology and Hepatology at the University of Wisconsin School of Medicine and Public Health. Dr. Rice completed his medical degree at the University of Nebraska College of Medicine. He completed his Internal Medicine training and served as Chief Resident at McGaw Medical Center of Northwestern University in Chicago, IL. He completed Gastroenterology and Hepatology and Transplant Hepatology fellowships at the University of Wisconsin Hospital and Clinics. He currently serves as a staff transplant hepatologist.

    Dr. Rice’s clinical and clinical research interests include management of alcohol-associated liver disease (ALD), alcohol use disorder, and liver transplant selection and liver transplant outcomes in ALD. Dr. Rice serves as the Chair of the Global Outreach subcommittee in the AASLD ALD special interest group.

  • 2020 Webinar: Dietary Recommendations for NAFLD Patients: What Do I Tell My Patients?

    Contains 2 Component(s) Recorded On: 08/19/2020

    Webinar hosted by the Non-alcoholic Fatty Liver Disease Special Interest Group on August 19, 2020.

    The purpose of this webinar is to provide the audience with the most current data regarding dietary intervention in NAFLD. The first talk "How Much Weight Should I Lose?" will focus on: he amount required for weight loss; changes in histology; and likelihood of success and exercise data. The second talk "Which Diet Should I Follow and Which Food I Should Eat or Avoid?" will include: types of diet; data on international diets; alcohol use; coffee; red meat; fructose; and others. The third talk "How Should I Start My Diet and How Would I Follow Up?" will include practical examples from NAFLD clinics. A patient with NAFLD with join the presenter during the third talk. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Manuel Romero Gómez

    Manuel Romero Gómez (Sevilla, Spain, 1967) is Full-Professor of Medicine at the University of Seville, Spain. Digestive Diseases Department at Virgen del Rocío University Hospitals. Head of group for translational research in liver diseases (SeLiver) at Institute of Biomedicine of Seville (IBIS). Coordinator of the Spanish Registry of NAFLD/NASH (HepaMET) and co-coordinator of the EASL supported European Registry of NAFLD. Principal Investigator in the Spanish Network for Research in Digestive and liver diseases (CiberEHD). He is participating actively in NASH-related European Projects: Sub-project-7 leader at European project FLIP (2010-2013), National Leader (SPAIN) at LITMUS (2017-2022) and coordinator of NASH-PI (2020-2021) an international grant.

    Member of commission 527 from ISCIII and Spanish Agency for Evaluation of Research (AEI). He received the XI Award Javier Benjumea Puigcerver in investigation, Universidad de Sevilla-Focus Abengoa, 2014. He was awarded with the Medal of The City of Seville in 2016. He has published more than 300 peer-reviewed papers on gastrointestinal and liver diseases with H-index 59. He has protected 10 patents and participated as PI in more than 20 competitive grants for research.

    Michelle Long

    Michelle Long, MD, MSc is a clinical investigator and hepatologist at the Boston University School of Medicine and Boston Medical Center. Dr. Long is the Director of the Boston Medical Center’s Nonalcoholic Fatty Liver Disease (NAFLD) Research Center and she is the Director of Clinical Research for the Section of Gastroenterology & Hepatology in the Department of Medicine. Dr. Long is primarily interested in patient-oriented research investigating fibrosis and inflammation in patients with NAFLD, including the overlap between NAFLD and cardiometabolic disease. Dr. Long is an investigator in the Framingham Heart Study where she is the Principal Investigator on a multi-year, multi-generational effort to evaluate the genetic and clinical correlates of liver fat and fibrosis as measured by transient elastography. She is the Principal Investigator for several ongoing Phase II and Phase III clinical trials in NAFLD. Dr. Long has received research funding from the National Institute of Health, Echosens Corporation, Gilead Sciences, The Doris Duke Research Foundation, and Boston University. She serves on the Liver-Biliary Council for the American Gastroenterological Association and on the Training and Workforce Committee for the American Association for the Study of Liver Diseases. Dr. Long is also an Associate Editor for Liver International.

    Zachary Henry

    Zachary Henry, MD is a transplant hepatologist at the University of Virginia in Charlottesville, Virginia. He works in our general hepatology and liver transplant clinics. In 2015, Dr. Henry started a specific clinic for patients with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis that is focused on lifestyle interventions for weight management. This clinic is a multi-disciplinary clinic run in conjunction with UVA endocrinology and cardiology specialists to approach related issues of metabolic syndrome in these patients. To that end , he underwent training in Obesity Medicine in 2017 and became certified by the American Board of Obesity Medicine in 2018. His research interests focus on lifestyle modfications for non-alcoholic fatty liver disease and the potential impact different groups of medications may have on these interventions.

    Wayne Eskridge

    Wayne Eskridge worked as an electrical engineer in software and electronics through a 50-year professional career. Eskridge held executive positions in both public and private corporations with worldwide responsibilities, and from startups to Fortune 500 firms. He was first diagnosed with liver disease in 2010, which progressed to cirrhosis by 2015. He has successfully managed his disease and as a result he became aware of an acute need for an educational resource from a patient perspective. His desire to help others avoid his experiences led him to the decision to become a patient advocate and to create the Fatty Liver Foundation.

    Mazen Noureddin (Moderator)

    Mazen Noureddin, MD, MHSc, is the founding director of the Fatty Liver Program at Cedars-Sinai Medical Center. He is a faculty at the Division of Digestive and Liver Diseases which was ranked #2 in gastroenterology and gastrointestinal surgery in the 2019 US News and World Report.

    His focus is on clinical and translational research in the area of NAFLD. Dr. Noureddin has conducted more than 30 investigational clinical studies of novel treatments for NASH. In addition, he has an interest in non-invasive testing and biomarkers of the field, especially metabolomics, serum biomarkers, trainset elastography, and magnetic resonance imaging techniques. Dr. Noureddin has published in all these areas. He is a member of the Liver Forum (FDA-AASLD-Academic Colloquium), standardizing pathways to translate therapeutic agents to clinical practice. He has given many invited lectures on NAFLD/NASH at national (e.g. American Gastroenterological Association, AASLD) and international society meetings and serves on several steering committees / advisory boards for industry.

  • Fundamentals of Liver Disease - Non-Alcoholic Fatty Liver Disease (NAFLD) & Non-Alcoholic Steatohepatitis 2.0

    Contains 31 Component(s), Includes Credits

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    There is currently an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    Key topic areas:
    NAFLD: Diagnosis and Identification of Those at Risk of Disease Progression
    Pathogenesis of Non-alcoholic Steatohepatitis
    Non-Invasive Determination of Advanced Disease in NAFLD
    Lifestyle Interventions: Setting Goals and Recommendations
    Comorbidities in NAFLD: Cardiovascular Disease, Sleep Apnea, and Chronic Kidney Disease
    Bariatric Surgery: Is the Cure for NASH in the OR?
    Managing NASH Cirrhosis and Assessment for Liver Transplant
    Current Pharmacological Treatment Options for Non-Alcoholic Steatohepatitis (NASH)
    Emerging Treatments for Non-Alcoholic Steatohepatitis

    Release date: June 15, 2020
    Expiration date: June 14, 2023
    Time to complete each module: 30 minutes

    CREDITS OFFERED

    Continuing Medical Education (CME): For a maximum of 4.50 AMA PRA Category 1 Credits™ 
    Continuing Education (CE): For a maximum of 4.50 Contact Hour
    You may only earn one Continuing Education Credit type- either CE or CME

    Maintenance of Certification (MOC): For a maximum of 4.50 MOC Points

    COMPONENTS
    Online presentations comprised of PowerPoint slides and accompanying audio, online pre- and post-tests and evaluations:
    -9 online, narrated modules 15 to 20 minutes in length 
    -Pre- and post-test questions for each module
    -Evaluation for CE or CME credit offering 

    DIRECTIONS
    Click "Activate" to register for the enduring material. Review all section tabs before you begin. Select module of interest. Complete necessary components to claim either CE or CME, and MOC.

    COPYRIGHT
    All faculty in this activity have given their permission for publication ©2020 AASLD. 

    CONTACT INFORMATION
    For questions on CME and  MOC content or LiverLearning®, contact online_education@aasld.org
    For questions on CE credit for this enduring material, contact Certificate@AmedcoEmail.com

    Learning Objective:
    • Identify patients with liver disease, specifically NASH/NAFLD
    • Apply diagnostic tests appropriately
    • Discuss important counseling
    • Recognize treatment/referral priorities
    • Identify first line therapies for NASH/NAFLD
    • Refer to specialist in a timely and appropriate fashion

    This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

    Hepatologists
    Gastroenterologists
    Nurses
    Nurse Practitioners
    Pharmacists
    Physician Assistants
    Transplant Coordinators
    Surgeons
    Fellows/Trainees
    Primary Care Physicians
    Other healthcare providers

    CREDITS OFFERED 
    Continuing Medical Education (CME): For a maximum of 4.50 AMA PRA Category 1 Credits™ 
    Maintenance of Certification (MOC): For a maximum of 4.50 MOC Points
    Continuing Education (CE): For a maximum of 4.50 Contact Hours

    ACCREDITATION AND DESIGNATION STATEMENTS Continuing Medical Education (CME) 
    The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 4.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Maintenance of Certification (MOC) Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    image

    Continuing Education (Nursing Contact Hours)  In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 4.50 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

    CLAIMING CME CREDITS Physicians and other health care professionals for a maximum of 4.50 AMA PRA Category 1 Credits™ for this enduring continuing medical education material must completed by June 14, 2023

    CLAIMING ABIM MOC POINTS  Physicians seeking ABIM MOC credit must complete the enduring material by June 14, 2023. Requests for MOC after this date will not be honored. MOC Points will be reported to the ABIM by the end of each month through July 2023 for individuals who successfully complete MOC.

    CLAIMING CE CREDITS Nurses for a maximum of 4.50 contact hours for this enduring continuing education material must be completed by June 14, 2023

    HOW TO EARN AND CLAIM MOC POINTS For each module that you wish to claim MOC points for you must:

                 o    Complete the pre-test

                 o    Watch video presentation

                 o    Complete the post-test and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing score.)

                 o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

    MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

    MOC points are available for ABIM board certified physicians only.

    DISCLOSURE OF CONFLICTS OF INTEREST
    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

    The enduring material organizers, faculty, reviewers and staff have reported the following disclosures:

    Mary E. Rinella, MD, FAASLD
    Faculty
    Consulting: AbbVie, NuSirt, NGM Biopharmaceuticals, Novartis, Gilead, Intercept, Genfit, Enanta, BMS, Immuron, CymaBay, Merck, Viking, Madrigal, Genesis, Metacrine, Allergan, Thetis, Fractyl, 3vBio, Coherus, Terns, Boehringer Ingelheim and Takeda
    Editorial Board: Hepatology, Clinical Liver Disease (guest associate editor), Seminars in Liver Disease (associate editor in 2017)

    Arun J. Sanyal, MD, MBBS
    Faculty
    Consulting: Novartis, Merck, BMS, Boehringer Ingelheim, Nitto Denko, Tobira, Intercept, Genfit, Aredelyx, Akarna, Syntlogic, Fractyl, Pfizer, Jannsen, Exalenz, Novo Nordisk, Nordic Bioscience, Lilly
    Grant/research support: Intercept, Gilead, Tobira, Novartis, Astra Zeneca, Merck, BMS
    Stock Options: Genfit
    President of Sanyal Bio

    Leon A. Adams, MBBS, FRACP, PhD
    Faculty
    Patents regarding Hepascore
    Employer has a licensing agreement with Quest Diagnostics regarding its commercialization

    Brent Neuschwander-Tetri, MD
    Faculty
    Consulting: Allergan, Allysta, Arrowhead, ARTham, Axcella, Blade, Boehringer-Ingelheim, Bristol-Myers Squibb, Conatus, Consynance, Cymabay, Durect, Enanta, Ferring, Fortress, Gelesis, Genfit, Gilead, High Tide, Histolndex, Intercept, Lipocine, Llama, Madrigal, Medimmune, Merck, Metacrine, Mundipharma, NGM, pH-Pharma, Prometheus and Siemens
    Grants/research support: Allergan, BMS, Cirius, Cymabay, Enanta, Galectin, Genfit, Gilead, Intercept, Madrigal, NGM and Prometheus

    Kathleen E. Corey, MD, MPH, MMSc
    Faculty
    Nothing to disclose

    Philippe Mathurin
    Faculty
    Financial Interests: MSD, Abbvie, Gilead Sciences, Bristol-Myers Squibb, Verlyx, Intercept, Janssen-Cilag and Bayer Healthcare pharmaceutical companies

    Kymberly D. Watt, MD

    Faculty
    Co-investigator for industry studies supported by Conatus, Intercept Pharmaceuticals and Gilead

    Dawn M. Torres, MD
    Faculty
    Nothing to disclose

    Raj Vuppalanchi, MD, FAASLD
    Faculty
    Data Safety Monitoring Board for Industry or Commercial Enterprise: Enanta, Enyio and LabCorp/Covance
    Served as PI for multicenter clinical trials: Intercept, Gilead, Zydus Discovery, Novo Nordisk and Eli Lilly

    Sanjeeva Arora, MD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose 

    Lauren A. Beste, MD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Amanda J. Chaney, DNP, APRN, FNP-BC
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Royalities: Springer Publishing-Author

    Guadalupe Garcia-Tsao, MD, FAASLD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Advisory Board: Intercept, Conatus
    Scientific Consultant/Advisor to Industry or Commercial Enterprises, including Development of Education Presentations: Conatus, Galectin
    Research Grants: Intercept

    Leslie Hayes
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Minhhuyen Nguyen, MD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Vicki Shah, PA
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: Gilead, Intercept, AbbVie Advisory Board, Gilead Advisory Board

    Raj Vuppalanchi, MD, FAASLD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Data Safety Monitoring Board for Industry or Commercial Enterprise: Enanta, Enyio and LabCorp/Covance
    Served as PI for multicenter clinical trials: Intercept, Gilead, Zydus Discovery, Novo Nordisk and Eli Lilly

    Susan Zapatka, MSN
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Dominique Clayton
    AASLD Staff
    Nothing to disclose

    Denise Seise
    AASLD Staff
    Nothing to disclose

    Sheryl Morgan
    Amedco LLC Staff
    Nothing to disclose

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Acknowledgement of Commercial Support:
    No commercial support was received for this enduring material activity.

  • 2020 Webinar: Hepatitis C: Infection Beyond the Liver

    Contains 2 Component(s) Recorded On: 05/19/2020

    Webinar hosted by the Hepatitis C Special Interest Group on May 19, 2020.

    Extrahepatic manifestations of HCV contribute to its increased overall mortality rate in those infected relative to those who aren’t; associated cardiovascular, neoplastic and renal manifestations can contribute significantly to a patient’s truncated lifespan beyond liver-related morbidity. This webinar will address the recognition and the treatment of extrahepatic manifestations of chronic HCV infection. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Miklos Z. Molnar

    Dr. Miklos Z. Molnar is an Hungarian-American Transplant Nephrologist and an Associate Professor of Medicine at University of Tennessee Health Science Center, Memphis, TN. He is also affiliated with James D. Eason Transplant Institute in Methodist University Hospital, also in Memphis. Dr. Molnar serves as Director of AST Transplant Nephrology Program at James D. Eason Transplant Institute in Methodist University Hospital.

    Dr. Molnar obtained his MD and PhD from Semmelweis University, Budapest, Hungary. He received additional medical training in Hungary and board certified in internal medicine, nephrology and transplant medicine in Europe. Dr Molnar immigrated to US in 2010, spent two years as post-doc fellow at Harbor UCLA, and obtained his US residency and transplant nephrology fellowship at University of Tennessee Health Science Center, Memphis, Tennessee and nephrology fellowship at University of Toronto, Toronto, Canada. Dr. Molnar is board certified in internal medicine and nephrology.

    Dr. Molnar is an author of more than 240 articles in a field of nephrology and transplant medicine. He serves as editorial board member in several journals, and current Associate Editor in Transplant International. He also served as PI in a recent R21 grant.

    Francesco Negro

    Francesco Negro is Professor at the Departments of Medicine and of Pathology and Immunology of the University Hospitals of Geneva, Switzerland. He obtained his Medical Degree in 1982 at the University of Torino, Italy, where he also completed his postgraduate education in Gastroenterology. He was Visiting Scientist and then Assistant Professor at the Georgetown University School of Medicine, Rockville, MD, USA from 1986 to 1989, and Guest Researcher at the Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA in 1989.

    After having spent some time back in Torino, he joined the University Hospitals of Geneva, Switzerland, in 1994. He was appointed Full Professor of the Faculty of Medicine, University of Geneva in 2014. His research interests focus on viral hepatitis, especially on the pathogenesis of metabolic alterations induced by the hepatitis C virus, i.e. steatosis and insulin resistance. More recently, he has participated into numerous collaborative works on epidemiology and public health issues related to viral hepatitis.

    He has participated in several clinical trials in acute and chronic HCV, authoring or co-authoring more than 300 peer-reviewed manuscripts in the field of hepatology. After serving as Educational Councilor within the Governing Board of the European Association for the Study of the Liver (EASL), he is currently Treasurer of EASL for the period 2019-2024. He is also chairing the Swiss Hepatitis C Cohort Study, and is member of the updating panels of the clinical practice guidelines for HCV of the EASL and of the World Health Organisation.

    Harrys A. Torres

    Harrys A. Torres, MD, FACP, FIDSA, is an Associate Professor of Medicine in the Department of Infectious Diseases, Infection Control and Employee Health and an Adjunct Associate Professor, Department of Gastroenterology, Hepatology, and Nutrition at the University of Texas MD Anderson Cancer Center in Houston, Texas. He is board-certified in internal medicine, and infectious disease, with additional accreditations on HIV/AIDS and Tropical Medicine and Hygiene. He is the founder and director of the Hepatitis C virus (HCV) clinic at MD Anderson, the first established clinic in the US, and likely in the world, devoted to managing HCV in cancer patients.

    Dr. Torres is a member of numerous national committees for professional societies such as the Infectious Diseases Society of America, American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver and the American Society for Blood and Marrow Transplantation. He is the secretary of the AASLD Special Interest Group on HCV and the principal investigator for multiple research grants. His research interest is to facilitate translational research in the prevention, detection, and treatment of HCV in patients with cancer and hematopoietic cell transplantation. His work addressed the fact that HCV is a neglected condition in cancer patients. Additionally, he has discovered new associations between HCV and other cancers (e.g. Head and Neck cancers). He has also documented the effectiveness, benefits, and safety of antiviral therapy in HCV-patients with cancer including those with hepatocellular carcinoma and B-cell non-Hodgkin lymphoma.

    Dr. Torres is co-author of more than 100 articles published in peer-reviewed journals, including CA: A Cancer Journal for Clinicians, Gastroenterology, HEPATOLOGY, Journal of Hepatology, Journal of the National Cancer Institute, Lancet Haematology, American Journal of Gastroenterology, Leukemia, Clinical Infectious Diseases, Blood, Nature Reviews Clinical Oncology, Cancer, Liver International, and Journal of Viral Hepatitis with many of his publications accompanied by editorials. He has presented almost 130 abstracts in international meetings and written 8 book chapters. His work on HCV has been awarded multiple times by the AASLD and American Society of Clinical Oncology among others. Dr. Torres lectures widely nationally and internationally on HCV in cancer patients and trains infectious diseases and gastroenterology fellows in the diagnosis and management of HCV in this special patient population. By providing evidence and innovative approaches, his body of work has changed the standard of care for HCV-infected cancer patients.

    Brian Pearlman (Moderator)

    Brian L. Pearlman, MD is Medical Director for Wellstar Atlanta Medical Center’s Center for Hepatitis C in Atlanta Georgia. He is also Professor of Medicine at the Medical College of Georgia and Professor of Medicine at Emory School of Medicine. Dr. Pearlman completed his medical degree at the University of Miami, Florida and his post-graduate training included both Diagnostic Radiology at University of Texas-Southwestern and Internal Medicine at Baylor University-Dallas, Texas.

    Dr. Pearlman is Faculty for the American College of Physicians (FACP), Fellow of the American Association for the Study of Liver Diseases (FAASLD), and members of the American Academy of HIV Medicine, and the American Gastroenterological Association. He sat on the Board of Directors for The American Liver Foundation’s Southeast Chapter. Dr. Pearlman is widely published in leading journals such as The Lancet, Gastroenterology, HEPATOLOGY, The American Journal of Gastroenterology, The Lancet Infectious Disease, Clinical Infectious Diseases and The American Journal of Medicine.

    Dr. Pearlman is active in both patient care and in teaching physicians. He has been the recipient of numerous teaching awards, and also an active investigator in multiple hepatitis C-related trials, some of which are in collaboration with the CDC’s Division of Viral Hepatitis.

  • 2020 Webinar: Chronic Hepatitis C 101: The Basics

    Contains 2 Component(s) Recorded On: 04/28/2020

    Webinar hosted by the Hepatitis C Special Interest Group on April 28, 2020.

    As chronic hepatitis C infection therapy moves outside the realm of specialty care, more providers want to be well-versed in both identifying patients and treating them appropriately. This webinar is designed for the HCV-treating novice. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Lisa Catalli

    Lisa Catalli is a Nurse Practitioner at the University of California, San Francisco’s Viral Hepatitis Center and Liver Transplant Clinic. She earned her Master’s Degree from UCSF School of Nursing in 1995 and has been working in the field of Hepatology since 2010. She has been treating HCV since the dawn of direct-acting antiviral therapy, and served as a co-investigator in several multi-center clinical trials. Her expertise in HCV treatment has led to multiple educational and leadership activities in HCV elimination. She has worked to disseminate knowledge about HCV through mentoring students and didactic presentations and workshops. She is a key clinical faculty in the UCSF Project ECHO program which uses multi-point video conferencing to build knowledge-sharing networks with community providers to build the capacity for care of HCV patients throughout California.

    She is also part of an interdisciplinary team to improve access and linkage to HCV care through a creative, innovative model of mobile liver care clinic (UCSF DeLiver Care) that is co-localized at syringe exchange/medically assisted treatment centers for vulnerable populations. She has been a Hepatology Associates member of AASLD for 10 years with leadership roles in the HCV SIG and the Hepatology Associates Committee, serving on committees for the planning of AASLD educational programs, moderating educational sessions, and selecting NP/PA fellowship awards.

    Natarajan Ravendhran

    Dr. Ravendhran is a hepatologist in Baltimore, Maryland. He is trained in hepatology by Dr. Schiff at University of Miami. He is board-certified in gastroenterology and transplant hepatology. He is a medical director for the research department in Digestive Disease Associates in Baltimore. He holds faculty position at Johns Hopkins University as a clinical assistant professor in the department of medicine. He is a Fellow of American Association for Study of Liver Diseases.

    He is actively involved in clinical trials, teaching and having a busy clinical practice. He has conducted more than 100 clinical trials in hepatology regarding chronic hepatitis C treatment, hepatitis B treatment and currently involved in many clinical trials with non-alcoholic fatty liver disease. He has published in Journal of Hepatology, Journal of American College of Gastroenterology, and New England Journal of Medicine.

    Brian Pearlman (Moderator)

    Brian L. Pearlman, MD is Medical Director for Wellstar Atlanta Medical Center’s Center for Hepatitis C in Atlanta Georgia. He is also Professor of Medicine at the Medical College of Georgia and Professor of Medicine at Emory School of Medicine. Dr. Pearlman completed his medical degree at the University of Miami, Florida and his post-graduate training included both Diagnostic Radiology at University of Texas-Southwestern and Internal Medicine at Baylor University-Dallas, Texas.

    Dr. Pearlman is Faculty for the American College of Physicians (FACP), Fellow of the American Association for the Study of Liver Diseases (FAASLD), and members of the American Academy of HIV Medicine, and the American Gastroenterological Association. He sat on the Board of Directors for The American Liver Foundation’s Southeast Chapter. Dr. Pearlman is widely published in leading journals such as The Lancet, Gastroenterology, HEPATOLOGY, The American Journal of Gastroenterology, The Lancet Infectious Disease, Clinical Infectious Diseases and The American Journal of Medicine.

    Dr. Pearlman is active in both patient care and in teaching physicians. He has been the recipient of numerous teaching awards, and also an active investigator in multiple hepatitis C-related trials, some of which are in collaboration with the CDC’s Division of Viral Hepatitis.

  • 2020 Webinar: Prevention and Management of Ascites in Cirrhosis: Controversies and New Approaches

    Contains 2 Component(s) Recorded On: 03/10/2020

    Webinar hosted by the Portal Hypertension Special Interest Group on March 10, 2020.

    This webinar will review recent important advances in understanding of how to care for patients with cirrhosis and ascites. Specifically, it will discuss how to risk stratify patients for ascites and new strategies for ascites prevention. In addition, it will address evidence-based approaches to the management of ascites among patients who have chronic kidney disease, a challenging and common clinical scenario. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Scott W. Biggins (Moderator)

    Dr. Scott W. Biggins is Chief of Hepatology, Director of the Liver Care Line for UW Medicine, and Director of the Center for Liver Investigation Fostering Discovery (C-LIFE) at the University of Washington. Dr. Biggins is a national recognized clinician and researcher in the field of Hepatology. He received his undergraduate degree in chemical engineering (bioengineering option) from the University of California, Los Angeles (1994) and his medical degree from the University of Southern California (1999). He completed a residency in Internal Medicine at Oregon Health & Science University (2002) and his Gastroenterology fellowship training at the University of California, San Francisco (2005). He was also awarded a Master’s degree in Clinical Research from the University of California, San Francisco (2006).

    Dr. Biggins' clinical interests are the risk reduction and management of complications of end-stage liver disease, and the clinical evaluation and care of liver transplant candidates and recipients. He has been recognized as a fellow of American Association for the Study of Liver Diseases (FAASLD), American Society of Transplantation (FAST), and American Gastroenterological Association (AGAF). He is Vice Chair of the AASLD Special Interest Group (SIG) for Portal Hypertension.

    His research is focused on complications of portal hypertension, improving recipient and donor selection for liver transplantation and revising organ allocation algorithms in order to maximize patient outcomes. He has received research funding from the American Liver Foundation, National Institutes of Health and the Agency for Healthcare Research and Quality. He has published more than 75 papers in peer-reviewed journals including the New England Journal of MedicineGastroenterology, HEPATOLOGY, and Liver Transplantation.

    Elizabeth Verna (Moderator)

    Dr. Elizabeth Verna is an Associate Professor of Medicine in the Center for Liver Disease and Transplantation and Division of Digestive and Liver Diseases at Columbia University, where she practices as transplant hepatologist.

    In addition, Dr. Verna has an active clinical research program in end-stage liver disease and liver transplantation and is the Director of Clinical Research for the Columbia University Transplant Clinical Research Center.

    Juan G. Abraldes

    Dr. Juan G. Abraldes is a Transplant Hepatologist, Professor and Director of the Liver Unit at the University of Alberta, Edmonton, Canada. He gained his MD in 1995 from the University of Santiago de Compostela, Spain, and got his Board Certificate in Gastroenterology and Hepatology at the Liver Unit, Hospital Clinic, University of Barcelona (2000). He did a postdoctoral training at Yale University (2003–2004). He was a faculty member of the Liver Unit, at Hospital Clinic Barcelona, until 2013, when he moved to the University of Alberta.

    He has published more than 200 papers on the pathophysiology, diagnosis and management of end-stage liver disease. He has co-authored the international Baveno guidelines for the management of portal hypertension in 2005, 2010 and 2015. He is the co-author of the American Association for the Liver Clinical Guidance for the management of varices and variceal bleeding in cirrhosis and was the chair of the AASLD Special Interest Group in Portal Hypertension between 2017 and 2018.

    Florence Wong

    Florence Wong, MD is a full professor at the University of Toronto and staff Hepatologist at the Toronto General Hospital, Ontario, Canada. She received her medical degree from the University of Melbourne, Australia and completed her postgraduate training in Australia and in Toronto, Canada. Apart from caring for a large population of patients with advanced liver cirrhosis, Dr. Wong has been active in research in the pathogenesis of portal hypertension, ascites formation, liver-kidney interaction, including the development of hepatorenal syndrome, and renal failure in cirrhosis for the past 28 years. She has received research funding from various funding agencies including the Canadian Institutes of Health Research, Canadian Liver Foundation and the National Institutes of Health.

    She has been the Secretary of the International Ascites Club, organizing two international meetings on the complications of ascites, she also held the position as the Chair of the Education Committee of the Canadian Association for the Study of the Liver. Recently, she served as the Chair of the "Acute-on-Chronic Liver Failure Special Interest Group" of the American Association for the Study of the Liver, and organizer of the Single Topic Symposium of Acute-on-Chronic Liver Failure. Currently, she is the Deputy Editor of Liver Transplantation. She is also the recipient of the Gold Medal from the Canadian Liver Foundation and the Canadian Association for the Study of the Liver for her contribution to academia in Hepatology.

    She has published widely on the topics related to ascites, and renal dysfunction in cirrhosis. She has more than 200 peer-reviewed publications as well as contributing regular reviews, book chapters and editorials on similar topics. She is currently on the writing committee to write the guidelines for the management of refractory ascites for the American Association for the Study of the Liver. Most recently, she has been responsible for putting together a landmark international document defining renal failure in cirrhosis.

  • 2020 Webinar: Implementation Science of Patient Reported Outcomes (PROs)

    Contains 2 Component(s) Recorded On: 02/27/2020

    Webinar hosted by the Public Health/Health care Delivery Special Interest Group on February 27, 2020.

    There is increasing interest to integrate patient reported outcomes (PROs) within routine practice to enhance and inform clinical care. It has shown to improve patient- provider communication, provider awareness of symptoms, tailored symptom management and enhanced quality of life. There is minimal knowledge on how to integrate PROMs within routine busy hepatology practice, and how to respond to the symptom scores assessed. We propose to conduct a webinar to discuss role of PROs in Hepatology, methods to integrate PROs within routine care, and learn how PROs are linked with healthcare quality. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Mayur Brahmania (Moderator)

    Dr. Mayur Brahmania is an Assistant Professor of Medicine at Western University practicing in Hepatology and Transplant Hepatology. After training in general and transplant Hepatology at the Toronto General Hospital: Toronto Centre for Liver Disease he undertook a research fellowship and earned a Masters of Public Health (MPH) degree at the Harvard TH Chan School of Public Health in Boston, MA. He also holds advanced certification from the Centre for Quality Improvement and Patient Safety (CQUIPS).

    Dr. Brahmania has been involved with the Choosing Wisely Canada (CWC) campaign as the Canadian Association for the Study of Liver Quality Lead. In this leadership role, he led the development of the 'top 5' list recommendations for Hepatology and his group is currently working to develop strategies to benchmark quality indicators for liver disease across Canada. 

    Dr. Brahmania is the current chair of the Gastroenterology Quality Improvement and Innovation Committee at Western University and currently focuses his research interests around quality improvement initiatives to advance and standardize quality of care in patients living with liver disease; many of these leading to publications in peer reviewed journals and presentation. 

    Rachel Sisodia

    Rachel Sisodia, MD is a gynecologic oncologist specializing in the care of women with cancer.  Her area of excellence is Clinical Expertise/Innovation in Surgery and Patient Reported Outcomes. Currently, she spends time serving as Medical Director for the Massachusetts General Physicians Organization (MGPO) and Medical Director for Partners Healthcare, where she is the Physician Executive responsible for the implementation, management and strategy of Patient Reported Outcomes (PROs) within the Partners Enterprise. In 2014, she joined the faculty at MGH and HMS, where she provides clinical care, supervise trainees and conduct research on operative/ peri-operative care with a goal of improving surgical outcomes for women with gynecologic malignancy. In addition to her work at MGH and HMS, she also travels to Southern New Hampshire Medical Center four days a month, where she works in a largely underserved area. 

    Dr. Sisodia has focused on developing best surgical practices in gynecologic oncology within her scope as a gynecologic oncologist. This work has resulted in peer reviewed publications on topics such as the role of hysterectomy in trophoblastic disease, the utility of the Surgical Apgar Score, debulking surgery for survival in ovarian cancer and risk factors for hospital readmission within 30 days of surgery.  She has presented this work on regional, national and international levels. This has taken the form of local and regional grand rounds, as well as multiple presentations of original research at the New England Association of Gynecologic Oncologists (NEAGO), where she won the 2012 award for Best Scientific Presentation. On a national scale her work has been presented at annual meetings for the Society of Gynecologic Oncology, Society for Gynecologic Investigation and the American Society for Clinical Oncology. She also spoken internationally on the evolving role of hysterectomy in the management of trophoblastic disease and have been instrumental in creating a monthly gynecologic oncology tumor board at Southern New Hampshire Medical Center where surgical and post-operative management is reviewed via an evidence-based approach, elevating the level of gynecologic cancer care in the community.    

    Manisha Verma

    Manisha Verma, MD, MPH, currently serves as the Director of Research at the Department of Digestive Diseases and Transplantation at Einstein Healthcare Network, Philadelphia, and as the Assistant Professor of Medicine, Research at Sidney Kimmel Medical College. Her program of research focuses on patient centered outcomes research (PCOR) within Hepatology and beyond.  She and her team received a 15 million research award from the Patient Centered Outcomes Research Institute to conduct a multi-site cluster randomized study to compare two models of palliative care delivery for ESLD. She has contributed to advances in knowledge of clinical applications of Health Services Research, specifically in the areas of clinical integration of patient reported outcomes assessments,  integrated care models (palliative care and behavioral health), and population-based health approaches. 

    In her role, she is responsible for promoting and facilitating leading edge research, including collaborative and interdisciplinary research, in areas related to the mission of the Department (to advance patient care, education and new treatments for liver diseases). She serves as the Steering Committee member for the American Association for Study of Liver Diseases (AASLD) Public Health / Healthcare Delivery Group and as the Vice Chair for the Education Subcommittee. Dr. Verma has won both the Albert Einstein Society Innovative Awards and Albert Einstein Society Research Awards as a Principal Investigator since 2015 onwards.  The studies supported from these awards have led to development of a PCOR Pillar within the Department. 

  • 2020 Webinar: NLRB - How Is It Working So Far?

    Contains 2 Component(s) Recorded On: 02/20/2020

    Webinar hosted by the Liver Transplantation journal on February 20, 2020.

    In the Spring of 2019, the National Liver Review Board was put into place. The purpose is to provide greater uniformity in assigning MELD exception scores. We have early data describing the initial outcomes of patients requesting MELD exception scores. There are also some early "lessons learned" in how to improve the process. Dissemination of this data would be helpful for practitioners requesting MELD scores for their patients. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    James F. Trotter

    Dr. Trotter is the Director of General and Transplant Hepatology at Baylor University Medical Center, part of Baylor Scott & White Health, and is fellowship-trained in hepatic transplantation and gastroenterology. His primary interests include end-stage liver disease, living donor liver transplantation, and the management of liver transplant candidates and recipients.

    Dr. Trotter works closely with local physicians to support the management and treatment of patients with liver disease and evaluate possible candidacy for transplantation at the liver outreach clinic in the Austin area. Dr. Trotter completed his medical training at University of Texas Southwestern Medical Center in Dallas before receiving fellowship training in gastroenterology and hepatic transplantation at Duke University Medical Center.

  • 2020 Webinar: Are You Digitally Secure?

    Product not yet rated Contains 2 Component(s) Recorded On: 02/18/2020

    Webinar hosted by the Communications and Technology Committee on February 18, 2020.

    Today’s high-profile hacks of major organizations and institutions have increased awareness of the issues of digital security, yet most people are compromising their privacy & security on a regular basis, which can put themselves – and their institution – at risk. Attendees at this webinar will better understand the digital risks and learn to separate truth from hype about how secure their presence is.

    Identify critical terms about digital security and privacy
    Understand how to best keep your personal digital presence from being compromised
    Learn over 5 tools that will greatly increase your online protection

    We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    James Spellos

    James Spellos is the President of Meeting U, a company specializing in helping people become more productive and comfortable with technology.

    Jim is certified as a Microsoft Office Specialist (MOS). He delivers more than 100 seminars annually on how to use technology more efficiently, and how it is altering the nature of business. He was a faculty member at New York University, teaching in the School of Professional and Continuing Studies for over 25 years. He was honored with both their Award for Teaching Excellence and their Outstanding Service Award.

    In 2014 Jim joined the Board of Directors for Rock and Wrap It Up, an anti-poverty, anti-hunger think tank, which supports food recovery for over 43,000 agencies in North America by recovering excess food from events. Jim co-created for them their Whole Earth Calculator app, which helps organizations identify the quantity of food donated and carbon footprint reduced by an organization helping to recover excess food from events.

    Jim is an accomplished musician and songwriter, and released his first solo recording, Stroke of Genius, at the end of 2019.